Safety and Efficacy of KTE-X19 in Adults With Relapsed/Refractory Chronic Lymphocytic
What is the safety and efficacy of KTE-X19 in adults with relapsed/refractory chronic
lymphocytic leukemia (r/r CLL)?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
Participants will receive conditioning chemotherapy (fludarabine and cyclophosphamide),
followed by the investigational treatment, KTE-X19. KTE-X19 is a CAR-T Cell Therapy
Study Reference #: IBMT18146
Lead Researcher (Principal Investigator)
Lead Researcher: Patrick Reagan
Study Contact InformationStudy Coordinator: Andrew Bui
Phone: (585) 276-4405
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search